Nursing Care for Ovarian Cancer Patients with Intraperitoneal Chemotherapy

[[abstract]]卵巢癌素有「沉默殺手」之稱，高居女性癌症死亡率之首位。卵巢癌標準治療為減積手術輔以鉑藥物之化學治療，以期延長病人的存活期。美國婦科腫瘤學會之臨床研究顯示接受減積手術後輔以靜脈合併腹腔內化學治療之卵巢癌個案其平均生存率以及平均無惡化生存時間均高於僅接受靜脈化學治療之個案，成為治療卵巢癌一項新的選擇方式。然而腹腔內化學治療費用較高、副作用大加上導管相關的併發症，成為此項治療的一大挑戰。本文提供臨床照護人員對於腹腔內化學治療可能產生的毒性副作用及併發症之認識，作為照護腹腔內化學治療患者之參考指引。 Ovarian cancer, known as a ＂silent killer＂, is the leading cause of gynecologic cancer death. Standard treatments for ovarian cancer are debulking surgery combined with platinum chemotherapy drugs to prolong the survival of patients. According to clinical trials run by the American Society of Gynecologic Oncology, patients who received intraperitoneal (IP) chemotherapy survived longer on average than patients who received intravenous chemotherapy alone. Thus, intraperitoneal chemotherapy is a new potential approach for treating ovarian cancer patients. However, the toxicities and undesirable complications of IP chemotherapy are the major challenges of this treatment approach. This article helps nurses recognize the toxicities and complications of IP chemotherapy and may be used as reference for future revisions to patient care guidelines